You are here

Join FDA Officials as They Discuss the Agency’s Overhaul of the Regulatory Review Process to Bring Innovative and Effective Drugs and Devices to Market

At this year’s ASCRS•ASOA Annual Meeting, join the ASCRS Food and Drug Administration (FDA) Committee on Sunday, April 15 from 1:00–2:30 p.m. for the symposium, “Accelerating Drug and Device Innovation: FDA’s Reorganization and Overhaul of the Regulatory Review Process to Bring Innovative and Effective Products to Market,” highlighting recent initiatives taken by the FDA to accelerate innovation, including the FDA’s reorganization efforts within the Division of Ophthalmic and Ear, Nose and Throat Devices (DOED) and the Center for Drug Evaluation and Research (CDER).

Malvina B. Eydelman, MD, director of the DOED, will join us to discuss the reorganization of the device center to streamline the approval process of new devices for ophthalmology. Peter Stein, MD, deputy director of FDA’s CDER, will discuss the reorganization of the drug center, particularly in terms of how reviews are conducted, and how the new structure will bring faster decision-making and innovation in the field of ophthalmology.

If you need additional information, please contact Jillian Winans, regulatory affairs specialist, at jwinans@ascrs.org or 703-591-2220.